Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: The article by Dr de Lemos et
al1 reporting the results of phase Z of the
A to Z trial and the accompanying editorial by Dr Nissen2 provide
important new information about event reduction by statins. Differences between
conclusions of the Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering (MIRACL)3 and the Pravastatin or Atorvastatin
Evaluation and Infection Therapy (PROVE IT)4 trials
may be due to differences in trial design.
Crouse JR. High-Dose Statins in Acute Coronary Syndromes. JAMA. 2005;293(1):36-39. doi:10.1001/jama.293.1.36-a